Cardiol Therapeutics Inc.
CRDL
Rank in Stocks
#18647
Cardiol Therapeutics Inc. operates as a clinical-stage life sciences company,... Cardiol Therapeutics Inc. operates as a clinical-stage life sciences company, primarily engaged in the discovery and advancement of treatments designed to combat fibrosis and inflammation within the context of cardiovascular diseases. Its flagship product, CardiolRx, is currently undergoing a significant Phase II/III international clinical trial. This extensive study is randomized, double-blind, and placebo-controlled, evaluating CardiolRx's efficacy and safety as a heart-protective therapy to mitigate cardiovascular and respiratory issues in individuals hospitalized with COVID-19. Concurrently, the trial also assesses CardiolRx's role in addressing acute myocarditis. Beyond this, the company is developing an injectable, subcutaneous formulation of CardiolRx, intended to target cardiac scarring and inflammation that contribute to the development and worsening of heart failure. Established in 2017, Cardiol Therapeutics Inc. is based in Oakville, Canada.
Share Price
$1.03
Last synced: 2026-11-09
Market Cap
$126.46M
Change (1 day)
3.52%
Change (1 year)
-0.96%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Cardiol Therapeutics Inc. (CRDL)
Category
Healthcare
EPS for Cardiol Therapeutics Inc. (CRDL)
EPS as of June 2026 TTM: $-0.26
According to Cardiol Therapeutics Inc.'s latest financial reports, its current EPS (TTM) is $-0.26. At the end of 2025 the company had an EPS of $-0.28, an increase over its 2024 EPS of $-0.36.
EPS history for Cardiol Therapeutics Inc. from 2017 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-0.26 | -8.07% |
| 2025 | $-0.28 | -20.06% |
| 2024 | $-0.36 | 7.02% |
| 2023 | $-0.33 | -8.03% |
| 2022 | $-0.36 | -37.48% |
| 2021 | $-0.58 | 6.57% |
| 2020 | $-0.54 | 32.97% |
| 2019 | $-0.41 | -16.22% |
| 2018 | $-0.49 | 737.35% |
| 2017 | $-0.06 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $6.50 | -2,625.80% |
DE
|
|
| $6.08 | -2,461.15% |
DE
|
|
| $1.55 | -702.41% |
JP
|
|
| $3.66 | -1,521.91% |
CH
|
|
| $0.45 | -274.83% |
IL
|
Questions about Cardiol Therapeutics Inc.'s earnings per share (EPS)
What is Cardiol Therapeutics Inc.'s earnings per share (EPS)?
Cardiol Therapeutics Inc.'s earnings per share (EPS) over the last twelve months is $-0.26, as of Jun 2026.
What was Cardiol Therapeutics Inc.'s earnings per share (EPS) in 2025?
In 2025, Cardiol Therapeutics Inc.'s earnings per share (EPS) was $-0.28, compared with $-0.36 in 2024.
How has Cardiol Therapeutics Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Cardiol Therapeutics Inc.'s earnings per share (EPS) was highest in 2025 ($-0.28) and lowest in 2021 ($-0.58).
How does Cardiol Therapeutics Inc.'s earnings per share (EPS) compare with similar companies?
Cardiol Therapeutics Inc.'s earnings per share (EPS) ($-0.26) is lower than that of all 5 similar companies listed above. The highest among them is MERCK Kommanditgesellschaft auf Aktien, with $6.50.